top of page

RDX-002, Response Pharmaceuticals’ lead candidate, is a first-in-class, potent, selective, and gut-specific small molecule inhibitor of microsomal triglyceride transfer protein (MTP) that is not systemically bioavailable. RDX-002 has been studied in multiple Phase 1 and Phase 2 clinical trials encompassing approximately 500 healthy subjects and patients dosed for up to 84 days. In these studies, RDX-002 was well tolerated and lowered post-prandial triglycerides and free fatty acids, reduced LDL cholesterol, lowered HbA1c in patients with diabetes, and reduced body weight without untoward side effects.

Clinical Trials

Completed Study: RDX-002-022-009 (Clinical Trials Gov) is a single-center Phase 1b trial enrolling 24 normal, healthy subjects to receive olanzapine for two weeks +/- RDX-002 for the second week. This study aims to determine the effect of RDX-002 on postprandial triglycerides in olanzapine-treated patients, explore effects on body weight and fasting lipids and demonstrate a lack of impact of RDX-002 on the steady-state pharmacokinetics of olanzapine.

Planned Study: RDX-002-023-010 is a double-blind, randomized, placebo-controlled, multicenter Phase 2b trial enrolling approximately 120 patients with schizophrenia and bipolar disease initiating olanzapine treatment, and will test the addition of RDX-002 or placebo for 12 weeks.


The primary outcome of the study is the difference in the mean percent change in body weight from baseline to week 12. Secondary and exploratory endpoints will include changes in postprandial triglycerides and fasting lipids. The trial is expected to begin enrollment in Q4 2024.

Planned Study: RDX-002-024-011 is a double-blind, randomized, placebo-controlled, single center Phase 2 trial enrolling approximately 40 patients discontinuing GLP-1 agonists semaglutide and tirzepatide for the treatment of obesity.


The primary objective of the study is to assess the difference in the mean percent change of post-prandial triglycerides from baseline in patients receiving RDX-002 vs placebo following discontinuation of GLP-1 agonist treatment for obesity. Secondary and exploratory endpoints will include changes in body weight and fasting lipids. The trial is expected to begin enrollment in Q3 2024.

Increased Mortality in Schizophrenia Due to Cardiovascular Disease – A Non-Systematic Review of Epidemiology, Possible Causes, and Interventions


Petter Andreas Ringen, John A. Engh, Astrid B. Birkenaes, Ingrid Dieset, and Ole A. Andreassen:    Front Psychiatry; 2014; 5: 137.

Schizophrenia, Antipsychotic Drugs, and Cardiovascular Disease 


Alexander H Glassman:  J Clin Psychiatry; 2005; 66 Suppl 6:5-1.


Schizophrenia and Increased Risks of Cardiovascular Disease


Charles H Hennekens , Alissa R Hennekens, Danielle Hollar, Daniel E Casey:  Am Heart J:; 2005 Dec;150(6):1115-21

Cardiovascular Disease in Patients with Severe Mental Illness


René Ernst Nielsen 1 2, Jytte Banner 3, Svend Eggert Jensen:   Nat Rev Cardiol;  2021 Feb;18(2):136-145.

Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia:

A Systematic Review and Meta-Analysis


Katsuhiko Hagi, Tadashi Nosaka , et al:   JAMA Psychiatry; 2021 May 1;78(5):510-518.

Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder

Rebecca C. Rossom, Stephanie A. Hooker, Patrick J. O’Connor, A. Lauren Crain and JoAnn M. Sperl‐Hillen:  JAHA; 11 (6) 2022.

Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain. 


Diana Grajales, Vitor Ferreira, and Ángela M. Valverde.  Cells. 2019 Nov; 8(11): 1336.

Biological Mechanism(s) Underpinning the Association between Antipsychotic Drugs and Weight Gain. 


Bruna Panizzutti , Chiara C. Bortolasci, et al. J Clin Medicine  J. Clin. Med. 2021, 10, 4095.

Compliance With Medication Regimens for Mental and Physical Disorders.


Joyce A. Cramer,  and Robert Rosenheck.  Psychiatric Services  Published Online:1 Apr 2006

Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia: A Comprehensive Review of Recent Literature. 


Jonathan P. Lacro, Laura B. Dunn, Christian R. Dolder, Susan G. Leckband, and Dilip V. Jeste. J Clin Psychiatry, published online: October 1, 2002.

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. 


Jeffrey A. Lieberman, M.D., T. Scott Stroup, M.D., M.P.H, et al. NEJM: 2005, 353 (12): 1209 – 1223.

bottom of page